PTC Therapeutics' Translarna loses EU conditional approval, but countries may allow continued use. PTC submitted four FDA ...

Shares of PTC Therapeutics fell after the company said regulators for the European Union won't renew authorization for its Translarna treatment for nonsense mutation Duchenne muscular dystrophy.

PTC Therapeutics said on Friday the European Commission will remove its inherited progressive muscle-wasting disorder from the region after an advisory panel reaffirmed a negative opinion of the drug ...

In a report released yesterday, Kristen Kluska from Cantor Fitzgerald initiated coverage with a Buy rating on Soleno Therapeutics (SLNO – ...

PTC Inc. is expanding with cloud-native tools and AI integration. Learn why PTC stock is a solid "Buy" on dips, driven by ...

US President Donald Trump has threatened to impose additional tariffs on the European Union and Canada if the two allies ...

PTC Therapeutics, Inc. today shared new data being presented from the Phase 3 APHENITY trial and subsequent open-label extension study at the 2025 American College of Medical Genetics and Genomics ...

The stock market is expected to remain directionless next week, but experts have identified eight stocks that could ...

Benchmark stock indices opened the week on a positive trajectory, bringing much-needed relief to Dalal Street investors. The ...

Learn more about whether PTC Therapeutics, Inc. or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ ...

Bajaj Broking Research recommends Piramal Pharma and PTC India for the upcoming week. Nifty is expected to remain volati ...

The Special Investment Facilitation Council (SIFC) endorsed the government’s deregulation policy for pharmaceutical sector announced in February 2024, stating that the sector was undergoing a ...